Myriad Genetics Inc. (MYGN)
NASDAQ: MYGN
· Real-Time Price · USD
7.20
-0.30 (-4.00%)
At close: Apr 29, 2025, 3:59 PM
7.20
0.00%
After-hours: Apr 29, 2025, 04:11 PM EDT
Myriad Genetics Revenue Breakdown
| Period Ending | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics Revenue | 161.7M | 177.1M | 157.8M | 130.5M | 150.5M | 177.6M | 170.4M | 200.5M | 203M | 189M | 179.7M | 179.2M | 178.8M | 187.9M | 185.2M | 183.9M | 165.1M | 173.7M | 177.4M | 182.6M | 171.9M |
| Diagnostics Revenue Growth | -8.70% | +12.23% | +20.92% | -13.29% | -15.26% | +4.23% | -15.01% | -1.23% | +7.41% | +5.18% | +0.28% | +0.22% | -4.84% | +1.46% | +0.71% | +11.39% | -4.95% | -2.09% | -2.85% | +6.22% | n/a |
| Other Segments Revenue | 5.6M | 12.3M | 15.3M | 14.7M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 12.6M | 12.4M | 12.7M | 13.1M | 10.7M | 11.6M |
| Other Segments Revenue Growth | -54.47% | -19.61% | +4.08% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | +1.61% | -2.36% | -3.05% | +22.43% | -7.76% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|
| Non-Us Revenue | 81.5M | 44.1M | 40.5M |
| Non-Us Revenue Growth | +84.81% | +8.89% | n/a |
| United States Revenue | 671.7M | 84.5M | 24.2M |
| United States Revenue Growth | +694.91% | +249.17% | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 139.1M | 144.9M | 140.6M | 32.6M | 170.4M | 218.2M | 151.7M | 146.5M | 130.5M | 127.1M | 110.6M | 141.5M | 180.2M | 134.8M | 145.5M | 132.9M | 124.1M | 107.4M | 132.9M | 135.6M | 135.5M | 149.8M | 140.6M | 135.2M | 129.9M | 121.4M | 115.1M | 115.4M | 115.2M | 122.1M | 122.1M | 120.3M | 111.9M | 91.3M | 90.5M | 90.8M | 86.5M | 97.5M | 91.28M |
| Selling, General, and Administrative Revenue Growth | -4.00% | +3.06% | +331.29% | -80.87% | -21.91% | +43.84% | +3.55% | +12.26% | +2.68% | +14.92% | -21.84% | -21.48% | +33.68% | -7.35% | +9.48% | +7.09% | +15.55% | -19.19% | -1.99% | +0.07% | -9.55% | +6.54% | +3.99% | +4.08% | +7.00% | +5.47% | -0.26% | +0.17% | -5.65% | 0.00% | +1.50% | +7.51% | +22.56% | +0.88% | -0.33% | +4.97% | -11.28% | +6.82% | n/a |
| Research and Development Revenue | 28.5M | 27.1M | 24.9M | 21M | 24M | 21.2M | 22.5M | 23.4M | 20.5M | 20.3M | 21.2M | 16.6M | 18.8M | 19.5M | 23.1M | 18.2M | 17.6M | 17.4M | 19.7M | 18.8M | 21.3M | 20.9M | 21.5M | 22.4M | 21.1M | 17.7M | 18.5M | 16.8M | 17.8M | 18.8M | 17.6M | 18.6M | 19.4M | 19.5M | 17.2M | 16.7M | 17.2M | 18.7M | 16.67M |
| Research and Development Revenue Growth | +5.17% | +8.84% | +18.57% | -12.50% | +13.21% | -5.78% | -3.85% | +14.15% | +0.99% | -4.25% | +27.71% | -11.70% | -3.59% | -15.58% | +26.92% | +3.41% | +1.15% | -11.68% | +4.79% | -11.74% | +1.91% | -2.79% | -4.02% | +6.16% | +19.21% | -4.32% | +10.12% | -5.62% | -5.32% | +6.82% | -5.38% | -4.12% | -0.51% | +13.37% | +2.99% | -2.91% | -8.02% | +12.16% | n/a |